Can‑Fite BioPharma Ltd. has finished enrolling patients in its Phase 2a study of the oral A3 adenosine receptor agonist Namodenoson for advanced pancreatic adenocarcinoma. The multicenter, open‑label trial enrolled patients whose disease had progressed after at least one prior therapy and is evaluating safety, clinical activity and pharmacokinetics at a dose of 25 mg twice daily in 28‑day cycles.
The company’s orphan drug designation from the U.S. Food and Drug Administration for pancreatic cancer underscores the potential commercial impact if the trial demonstrates meaningful activity. The enrollment milestone de‑risks the trial timeline, allowing the company to move forward with data collection and to generate the evidence needed to support future regulatory submissions and potential partnership opportunities.
Chief Scientific Officer Pnina Fishman said the completion “marks a significant step forward in the clinical development of Namodenoson in pancreatic cancer. With enrollment now complete and safety continuing to be favorable, we believe we are well positioned to generate meaningful efficacy top‑line data in Q3 2026.” The company expects top‑line efficacy data in the third quarter of 2026, a key milestone for its oncology pipeline.
Can‑Fite’s financial metrics indicate significant challenges, including negative margins and declining revenue growth. The clinical milestone is therefore a critical development that may help the company secure additional funding or partnership capital to sustain its research and development program.
The enrollment completion positions Can‑Fite to advance its strategy of bringing A3AR‑targeted therapies to market, while also expanding its pipeline with other candidates such as Piclidenoson for psoriasis and CF602 for erectile dysfunction. The milestone strengthens the company’s case for future regulatory submissions and partnership negotiations in a high‑need oncology indication.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.